Wall Street Access Asset Management LLC reduced its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,762 shares of the medical research company’s stock after selling 300 shares during the quarter. Wall Street Access Asset Management LLC’s holdings in Amgen were worth $572,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in AMGN. Kwmg LLC purchased a new position in shares of Amgen in the second quarter valued at $108,000. Mainstay Capital Management LLC ADV purchased a new position in shares of Amgen in the second quarter valued at $111,000. Braun Bostich & Associates Inc. purchased a new position in shares of Amgen in the first quarter valued at $113,000. WealthTrust Fairport LLC purchased a new position in shares of Amgen in the first quarter valued at $121,000. Finally, Gables Capital Management Inc. purchased a new position in shares of Amgen in the first quarter valued at $174,000. Institutional investors own 82.48% of the company’s stock.
Several research analysts have recently weighed in on AMGN shares. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $207.00 target price for the company in a research note on Tuesday, June 26th. Mizuho restated a “buy” rating and issued a $200.00 target price on shares of Amgen in a research note on Friday, June 22nd. BidaskClub upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Monday, June 18th. Jefferies Financial Group restated a “buy” rating and issued a $200.00 target price on shares of Amgen in a research note on Monday, July 16th. Finally, Morgan Stanley upped their target price on shares of Amgen from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, July 13th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $204.90.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, July 16th. The shares were sold at an average price of $195.71, for a total transaction of $298,457.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.27% of the stock is currently owned by corporate insiders.
NASDAQ AMGN opened at $197.39 on Friday. Amgen, Inc. has a 12 month low of $163.31 and a 12 month high of $210.19. The company has a debt-to-equity ratio of 2.03, a quick ratio of 3.12 and a current ratio of 3.39. The firm has a market cap of $134.17 billion, a price-to-earnings ratio of 15.69, a P/E/G ratio of 2.02 and a beta of 1.40.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, beating the Zacks’ consensus estimate of $3.52 by $0.31. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The firm had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $5.73 billion. During the same period in the prior year, the firm posted $3.27 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. On average, research analysts expect that Amgen, Inc. will post 13.96 EPS for the current fiscal year.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Story: Terms to Better Understand Call Options
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.